Sanofi (LON:0O59)
London
· Delayed Price · Currency is GBP · Price in EUR 82.47
-1.14 (-1.36%)
At close: Jul 3, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Total Vaccine | 8.30B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Total Vaccine Growth | 12.87% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | 3.21B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Opella Consumer Healthcare | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Opella Consumer Healthcare Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Dupixent | 13.07B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Dupixent Growth | 22.10% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Total Neurology & Immunology | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Total Neurology & Immunology Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Total Rare Diseases | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Total Rare Diseases Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Total Oncology | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Total Oncology Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Total Rare Blood Disorders | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Total Rare Blood Disorders Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Total Core Assets | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Total Core Assets Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Total Non-Core Assets | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Total Non-Core Assets Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Industrial | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Industrial Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Specialty Care | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Pharma | 32.78B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | 3.21B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | 3.21B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Other | -2.47B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Pharmaceutical Operating Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Pharmaceutical Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Vaccine Operating Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Vaccine Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Operating Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | -2.47B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Consumer Healthcare Operating Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Consumer Healthcare Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Biopharma Operating Income | 11.29B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Biopharma Operating Income Growth | 8.40% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Opella Consumer Healthcare (Post-2022 Reporting) Operating Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other (Post-2022 Reporting) Operating Income | 58.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other (Post-2022 Reporting) Operating Income Growth | 28.57% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | -2.47B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Other | 3.21B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | 3.21B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
United States | 19.99B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
United States Growth | 14.32% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe | 9.03B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Europe Growth | -5.17% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rest of World | 12.07B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rest of World Growth | -5.78% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | 3.21B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|